Richter Gedeon Nyrt.

Egis Gyogyszergyar Rt.

Richter Gedeon Vegyeszeti Gyar Rt

Richter Gegeon Nyrt.

Egis Gyoyszergyar Rt

Eva Schmidt

Istvan Gyertyan

Bela Kiss

Sandor Farkas

Eva Againe Csongor

Istvan Gacsalyi

Gabor Blasko

Katalin Saghy

Andras Egyed

Gyula Simig

Zoltan Budai

Gyorgy Domany

Judit Laszy

Gizella Bartane Szalai

Istvan Vago

Monika Vastag

Eva Bozo

Gyula Beke

Katalin Hornok

Eva Szentirmay

Zsolt Komlodi

Tibor Mezei

Marton Fekete

Gabor Nemeth

Janos Galambos

Imre Klebovich

Daniel Bozsing

Katalin Szemeredi

Gyula Lukacs

Karoly Tihanyi

Andras Bilkei-Gorzo

Judit Bajnogel

Aniko Miklos Nee Kovacs

Enik Szirt Nee Kiszelly

Gyula Grezal

Kalara Reiter Nee Esses

Katalin Baloghne Nemes

Miklos Abermann

Andras Bilkei Gorzo

Erzsebet Kaufmanne Bojti

Ildiko Ratz Nee Simonek

Ivan Jakoczi

Gyoergy Domany

Gabor Czira

Norbert Antal Kirschner

The present invention relates to new dopamine Dand Dligands of formula (I): wherein R1, R2 and Q are as described herein, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates and/or polymorphs thereof. The invention also relates to processes for preparing the same, to compositions containing the same and to their use in the treatment and/or prevention of conditions which requires modulation of dopamine receptors.

[object Object]

The present invention relates to metabolites of(thio)-carbamoyl cyclohexane derivatives, particularly, metabolites of trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoyl-cyclohexylamine and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing the same and to their use in the treatment and/or prevention of a conditions which requires modulation of dopamine receptors.

Metabolites of (thio) carbamoyl-cyclohexane derivatives

The present invention relates to new phenylsulfamoyl benzamide derivatives of formula (I) wherein

Benzamide derivatives as bradykinin antagonists

The present invention relates to new phenanthridine derivatives of formula (I), wherein the variables are as defined in the specification, to processes for producing the same, to pharmacological compositions containing the same and to their use in therapy or prevention of painful and inflammatory processes. 

Phenanthridine derivatives as bradykinin antagonists

The present invention relates to new dopamine Dand Dand serotonin 5-HTreceptor subtype preferring ligands of formula (I); wherein A represents alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or a group of formula &#x2014;NRR, wherein Rand Rrepresent independently a substituent selected from hydrogen, alkyl, alkenyl, aryl, heteroaryl or cycloalkyl or Rand Rform with the adjacent nitrogen atom and optionally with further heteroatom(s) a heterocyclic ring; m is an integer of 0 to 1; n is an integer of 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmacological compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine and/or 5-HTreceptors. 

Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions

1,7,7-trimethyl-bicyclo[2.2.1]heptane derivatives as anxiolytic agents

Novel basic ether of general formula (I), ##STR1## wherein R.sup.1 and R.sup.2 are independently hydrogen, halogen or C.sub.1-4 alkoxy, or together they represent a 3,4-methylenedioxy group,

Basic ethers and process for the preparation thereof

Growing community of inventors

Budapest, Hungary

Eva Schmidt